Investor FAQs
Show All
Where is NewAmsterdam Pharma's corporate headquarters?
NewAmsterdam Pharma is headquartered in Naarden, the Netherlands.
Where is the company incorporated?
NewAmsterdam Pharma is incorporated in the Netherlands.
When did NewAmsterdam Pharma go public?
NewAmsterdam began trading on NASDAQ under the ticker NAMS in November 2022.
What is NewAmsterdam Pharma’s fiscal year?
NewAmsterdam Pharma’s fiscal year end is December 31st.
How is NewAmsterdam Pharma stock traded?
NewAmsterdam Pharmaceuticals is traded on the NASDAQ exchange under ticker symbol NAMS.
What is the CUSIP number for NewAmsterdam Pharma?
CUSIP: N62509109
What is the ISIN number for NewAmsterdam Pharma?
ISIN: NL00150012L7
Does NewAmsterdam Pharma pay dividends?
No, the company does not currently pay dividends.
Who is NewAmsterdam Pharma's transfer agent?
Continental Stock Transfer and Trust Company.
Does NewAmsterdam Pharma have a direct stock purchase plan?
NewAmsterdam Pharma does not currently offer a direct stock purchase plan.
Who is NewAmsterdam Pharma's auditor?
Deloitte Accountants B.V.
Who is NewAmsterdam Pharma's legal counsel?
Covington & Burling LLP
How can I view documents NewAmsterdam Pharma has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?
Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financial Information portion of our Investor Relations website or directly from the SEC at www.sec.gov.
Whom should I contact regarding investor inquiries?
For investor inquiries, please contact hannah.deresiewicz@sternir.com.
How can I access NewAmsterdam’s whistleblower hotline?
The NewAmsterdam Pharma whistleblower services hotline can be accessed here: https://www.whistleblowerservices.com/NAMS.